Anticancer agent
The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.
1. A compound represented by the formula (IA):
wherein
R 1 in the number of n are each independently
hydrogen,
halogen,
C 1-6 alkoxy, or
two R 1 bonded to the adjacent carbon atoms on a benzene ring are optionally joined to form C 1-4 alkylenedioxy,
R 2 is
C 1-12 alkyl optionally substituted by one or two substituent(s) selected from substituent group α,
C 2-6 alkynyl optionally substituted by one or two substituent(s) selected from optionally substituted amino and optionally substituted monocyclic heterocyclyl group,
C 3-7 cycloalkyl,
phenyl,
phenyl C 1-6 alkyl, or
monocyclic heterocyclyl group,
R 3 is hydrogen,
n is an integer of 1-4 when R 1 is hydrogen,
n is 1 or 2 when R 1 is not hydrogen, and
the substituent group α consists of
hydroxy,
optionally substituted amino,
carboxy,
C 1-6 alkoxycarbonyl,
sulfo group,
di C 1-6 alkyl phosphoric acid group,
optionally substituted C 1-6 alkyl,
C 3-7 cycloalkyl,
C 3-7 cycloalkyl C 1-6 alkyl,
optionally substituted C 1-6 alkoxy,
optionally substituted phenyl,
optionally substituted phenyloxy,
phenyl C 1-6 alkoxy,
optionally substituted monocyclic heterocyclyl group,
optionally substituted C 1-6 alkylcarbonyl,
monocyclic heterocyclylcarbonyl,
optionally substituted C 1-6 alkylcarbonyloxy,
optionally substituted C 3-7 cycloalkylcarbonyloxy,
phenylcarbonyloxy,
monocyclic heterocyclylcarbonyloxy,
optionally substituted C 1-6 alkoxycarbonyloxy,
optionally substituted monocyclic heterocyclyl C 1-6 alkoxycarbonyloxy,
C 3-7 cycloalkyloxycarbonyloxy,
monocyclic heterocyclyloxycarbonyloxy,
optionally substituted monocyclic heterocyclyloxy,
tri C 1-6 alkylammonio,
optionally substituted C 1-6 alkylsulfonyl and
C 1-6 alkylsulfamoylcarbonyl,
or a pharmaceutically acceptable salt thereof.
2. A compound represented by the formula (I):
wherein
R 1 is hydrogen or halogen,
R 2 is
C 1-12 alkyl optionally substituted by one or two substituent(s) selected from substituent group α,
C 2-6 alkynyl optionally substituted by one or two substituent(s) selected from optionally substituted amino and optionally substituted monocyclic heterocyclyl group,
C 3-7 cycloalkyl,
phenyl
phenyl C 1-6 alkyl, or
monocyclic heterocyclyl group,
n is an integer of 1-4 when R 1 is hydrogen,
n is 1 or 2 when R 1 is not hydrogen, and
the substituent group α consists of
hydroxy,
optionally substituted amino,
carboxy,
C 1-6 alkoxycarbonyl,
sulfo group,
di C 1-6 alkyl phosphoric acid group,
optionally substituted C 1-6 alkyl,
C 3-7 cycloalkyl,
C 3-7 cycloalkyl C 1-6 alkyl,
optionally substituted C 1-6 alkoxy,
optionally substituted phenyl,
optionally substituted phenyloxy,
phenyl C 1-6 alkoxy,
optionally substituted monocyclic heterocyclyl group,
optionally substituted C 1-6 alkylcarbonyl,
monocyclic heterocyclylcarbonyl,
optionally substituted C 1-6 alkylcarbonyloxy,
optionally substituted C 3-7 cycloalkylcarbonyloxy,
phenylcarbonyloxy,
monocyclic heterocyclylcarbonyloxy,
optionally substituted C 1-6 alkoxycarbonyloxy,
optionally substituted monocyclic heterocyclyl C 1-6 alkoxycarbonyloxy,
C 3-7 cycloalkyloxycarbonyloxy,
monocyclic heterocyclyloxycarbonyloxy,
optionally substituted monocyclic heterocyclyloxy,
tri C 1-6 alkylammonio,
optionally substituted C 1-6 alkylsulfonyl and
C 1-6 alkylsulfamoylcarbonyl,
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 , wherein the substituent group α consists of
hydroxy,
optionally substituted amino,
carboxy,
C 1-6 alkoxycarbonyl,
sulfo group,
di C 1-6 alkyl phosphoric acid group,
C 1-6 alkyl,
C 3-7 cycloalkyl,
C 1-6 alkoxy,
optionally substituted phenyl,
optionally substituted phenyloxy,
phenyl C 1-6 alkoxy,
optionally substituted monocyclic heterocyclyl group,
optionally substituted C 1-6 alkylcarbonyl,
monocyclic heterocyclylcarbonyl,
optionally substituted C 1-6 alkylcarbonyloxy,
optionally substituted C 3-7 cycloalkylcarbonyloxy,
monocyclic heterocyclylcarbonyloxy,
optionally substituted C 1-6 alkoxycarbonyloxy,
optionally substituted monocyclic heterocyclyl C 1-6 alkoxycarbonyloxy,
C 3-7 cycloalkyloxycarbonyloxy,
monocyclic heterocyclyloxycarbonyloxy,
optionally substituted monocyclic heterocyclyloxy and
tri C 1-6 alkylammonio,
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 2 , wherein the substituent group α consists of
hydroxy,
optionally substituted amino,
carboxy,
C 1-6 alkoxycarbonyl,
sulfo group,
di C 1-6 alkyl phosphoric acid group,
C 1-6 alkyl,
C 3-7 cycloalkyl,
C 1-6 alkoxy,
optionally substituted phenyl,
optionally substituted phenyloxy,
phenyl C 1-6 alkoxy,
optionally substituted monocyclic heterocyclyl group,
optionally substituted C 1-6 alkylcarbonyl,
monocyclic heterocyclylcarbonyl,
optionally substituted C 1-6 alkylcarbonyloxy,
optionally substituted C 3-7 cycloalkylcarbonyloxy,
monocyclic heterocyclylcarbonyloxy,
optionally substituted C 1-6 alkoxycarbonyloxy,
optionally substituted monocyclic heterocyclyl C 1-6 alkoxycarbonyloxy,
C 3-7 cycloalkyloxycarbonyloxy,
monocyclic heterocyclyloxycarbonyloxy,
optionally substituted monocyclic heterocyclyloxy and
tri C 1-6 alkylammonio,
or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 2 , wherein
R 2 is C 1-6 alkyl optionally substituted by one or two substituent(s) selected from substituent group α, C 3-7 cycloalkyl, phenyl, phenyl C 1-6 alkyl, or monocyclic heterocyclyl group, and
the substituent group α consists of hydroxy, optionally substituted amino, carboxy, sulfo group, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy, phenyl and monocyclic heterocyclyl group,
or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 2 , wherein
R 2 is
(1) C 1-6 alkyl optionally substituted by one or two substituent(s) selected from hydroxy, optionally substituted amino, carboxy, sulfo group, di C 1-6 alkyl phosphoric acid group, monocyclic heterocyclyl group, optionally substituted C 1-6 alkoxy, optionally substituted C 1-6 alkylcarbonyloxy, monocyclic heterocyclylcarbonyloxy, C 3-7 cycloalkyloxycarbonyloxy and monocyclic heterocyclyloxycarbonyloxy;
(2) C 2-6 alkynyl optionally substituted by one or two substituent(s) selected from optionally substituted amino and monocyclic heterocyclyl group;
(3) monocyclic heterocyclyl group; or
(4) phenyl C 1-6 alkyl,
or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 2 , wherein
R 2 is
(1) C 1-6 alkyl optionally substituted by one or two substituent(s) selected from hydroxy, optionally substituted C 1-6 alkoxy, optionally substituted C 1-6 alkylcarbonyloxy and monocyclic heterocyclylcarbonyloxy; or
(2) C 2-6 alkynyl optionally substituted by one or two substituent(s) selected from optionally substituted amino and monocyclic heterocyclyl group; or
(3) monocyclic heterocyclyl group,
or a pharmaceutically acceptable salt thereof.
8. The compound according to any one of claims 1 to 7 , wherein R 1 is hydrogen, or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound according to claim 8 or a pharmaceutically acceptable salt thereof as an active ingredient.
10. A compound, which is
or a pharmaceutically acceptable salt thereof.
11. A compound, which is
or a pharmaceutically acceptable salt thereof.
12. The compound according to claim 2 , which is
13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 , 10 , and 11 or a pharmaceutically acceptable salt thereof as an active ingredient.
14. A pharmaceutical composition comprising a compound according to claim 12 as an active ingredient.
15. A method of treating cancer, cancer metastasis, and/or cancer recurrence in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 7 and 10 to 12 or a pharmaceutically acceptable salt thereof.
16. The method according to claim 15 , wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal cancer, prostate cancer, esophageal cancer, nasopharyngeal cancer, pituitary cancer, gallbladder cancer, thyroid cancer, salivary gland cancer, urinary bladder cancer, renal cell carcinoma, melanoma, hepatoma, cervical cancer, endometrial carcinoma, Kaposi's sarcoma, Ewing's sarcoma, medulloblastoma, sarcoma, brain tumor, gastric cancer, multiple myeloma, leukemia, and lymphoma.
17. A method of treating cancer, cancer metastasis, and/or cancer recurrence in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to claim 8 or a pharmaceutically acceptable salt thereof.
18. The method according to claim 17 , wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal cancer, prostate cancer, esophageal cancer, nasopharyngeal cancer, pituitary cancer, gallbladder cancer, thyroid cancer, salivary gland cancer, urinary bladder cancer, renal cell carcinoma, melanoma, hepatoma, cervical cancer, endometrial carcinoma, Kaposi's sarcoma, Ewing's sarcoma, medulloblastoma, sarcoma, brain tumor, gastric cancer, multiple myeloma, leukemia, and lymphoma.